Zelluna ASA (OSTO:ULTIO) 3-Year RORE % : -76.18% (As of Mar. 2026)


OSTO:ULTIO Zelluna ASA OSTO:ULTIO
28 GF Score
Price kr21.95
! 2 Warning Signs
View Full Analysis

What is Zelluna ASA 3-Year RORE %?

Zelluna ASA OSTO:ULTIO 28 3-Year RORE % is -76.18 as of Mar. 2026. GuruFocus rates OSTO:ULTIO with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,289 Biotechnology companies, Zelluna ASA ranks worse than 89.91% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Zelluna ASA's 3-Year RORE % for the quarter that ended in Mar. 2026 was -76.18%.

The industry rank for Zelluna ASA's 3-Year RORE % or its related term are showing as below:

OSTO:ULTIo's 3-Year RORE % is ranked worse than
89.91% of 1289 companies
in the Biotechnology industry
Industry Median: -11.44 vs OSTO:ULTIo: -76.18

Zelluna ASA  (OSTO:ULTIo) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Zelluna ASA 3-Year RORE % Related Terms


Zelluna ASA 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Zelluna ASA's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelluna ASA 3-Year RORE % Chart

Zelluna ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.69 6.29 1.91 -23.21 -60.69

Zelluna ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.02 -45.18 -53.82 -60.69 -76.18

OSTO:ULTIO vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, Zelluna ASA's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zelluna ASA 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelluna ASA's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Zelluna ASA's 3-Year RORE % falls into.


OSTO:ULTIO
28GF Score
Zelluna ASA OSTO:ULTIO
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelluna ASA 3-Year RORE % Calculation

Zelluna ASA's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -6--61 )/( -72.2-0 )
=55/-72.2
=-76.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -76.18 mean?
Zelluna ASA (OSTO:ULTIO) has a 3-Year RORE % of -76.18 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Zelluna ASA and its competitors. According to the industry distribution chart, Zelluna ASA ranks #1159 out of 1289 companies in the Biotechnology industry, placing it in the top 89.9%.
Is Zelluna ASA's 3-Year RORE % too high?
Zelluna ASA's current 3-Year RORE % is -76.18. Based on the distribution chart, Zelluna ASA ranks #1159 out of 1289 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zelluna ASA has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zelluna ASA ranks #1159 out of 1289 companies for 3-Year RORE %. This places Zelluna ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Zelluna ASA and its competitors. Zelluna ASA's current 3-Year RORE % is -76.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (OSTO:ULTIO) has a current 3-Year RORE % of -76.18. The current 3-Year RORE % is -76.18. Zelluna ASA's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Zelluna ASA (OSTO:ULTIO), the current 3-Year RORE % is -76.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelluna ASA Business Description

Other Exchanges ZLNA:Norway7UM0:Germany
Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
28GF Score

Get the complete analysis for OSTO:ULTIO

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.95
Price